Valentina Svicher

Summary

Affiliation: University of Rome Tor Vergata
Country: Italy

Publications

  1. pmc The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype
    Francesc Cunyat
    IrsiCaixa HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Germans Trias, Universitat Autonoma de Barcelona, Catalonia, Spain
    Retrovirology 9:15. 2012
  2. doi request reprint Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Acquir Immune Defic Syndr 55:336-44. 2010
  3. pmc Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Antimicrob Agents Chemother 53:2816-23. 2009
  4. doi request reprint Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure
    Valentina Svicher
    Department of Experimental Medicine, University of Tor Vergata Rome, Italy
    J Infect Dis 197:1408-18. 2008
  5. ncbi request reprint Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome, Tor Vergata, Rome, Italy
    J Antimicrob Chemother 58:714-22. 2006
  6. doi request reprint Dynamics of NRTI resistance mutations during therapy interruption
    Maria Trignetti
    Experimental Medicine Department, University of Rome Tor Vergata, 00133, Rome, Italy
    AIDS Res Hum Retroviruses 25:57-64. 2009
  7. ncbi request reprint Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy
    Maria Mercedes Santoro
    Department of Experimental Medicine, Tor Vergata University of Rome, Italy
    New Microbiol 29:89-100. 2006
  8. doi request reprint Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage
    Salvatore Dimonte
    University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Virus Res 168:73-83. 2012
  9. doi request reprint Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia
    Valentina Svicher
    University of Rome Tor Vergata, Italy
    Dig Liver Dis 42:902-7. 2010
  10. pmc Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs
    Claudia Alteri
    Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata Rome, Italy
    BMC Infect Dis 9:111. 2009

Detail Information

Publications41

  1. pmc The HR2 polymorphism N140I in the HIV-1 gp41 combined with the HR1 V38A mutation is associated with a less cytopathic phenotype
    Francesc Cunyat
    IrsiCaixa HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol IGTP, Hospital Germans Trias, Universitat Autonoma de Barcelona, Catalonia, Spain
    Retrovirology 9:15. 2012
    ....
  2. doi request reprint Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Acquir Immune Defic Syndr 55:336-44. 2010
    ..To investigate genotypic resistance profiles to emtricitabine + tenofovir (FTC + TDF) in-vivo and in-vitro, and compare them with lamivudine + tenofovir (3TC + TDF)...
  3. pmc Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Antimicrob Agents Chemother 53:2816-23. 2009
    ..This highlights the multiple roles of ENF (and perhaps other entry inhibitors) in modulating the correct interplay between the different HIV-1 genes and proteins during the HIV-1 life cycle...
  4. doi request reprint Specific enfuvirtide-associated mutational pathways in HIV-1 Gp41 are significantly correlated with an increase in CD4(+) cell count, despite virological failure
    Valentina Svicher
    Department of Experimental Medicine, University of Tor Vergata Rome, Italy
    J Infect Dis 197:1408-18. 2008
    ..We investigated the correlation of enfuvirtide (ENF)-associated gp41 mutational clusters with viroimmunological parameters, as well as the potential underlying mechanisms...
  5. ncbi request reprint Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome, Tor Vergata, Rome, Italy
    J Antimicrob Chemother 58:714-22. 2006
    ..To investigate gp41 variability and correlation with viro-immunological parameters in 54 HIV-1-infected patients receiving enfuvirtide added as single active drug to a failing regimen...
  6. doi request reprint Dynamics of NRTI resistance mutations during therapy interruption
    Maria Trignetti
    Experimental Medicine Department, University of Rome Tor Vergata, 00133, Rome, Italy
    AIDS Res Hum Retroviruses 25:57-64. 2009
    ..Overall, it seems that the loss of NRTI drug resistance mutations during TI is not an ordered process, and in the majority of patients occurs without specific interaction among mutations...
  7. ncbi request reprint Temporal characterization of drug resistance associated mutations in HIV-1 protease and reverse transcriptase in patients failing antiretroviral therapy
    Maria Mercedes Santoro
    Department of Experimental Medicine, Tor Vergata University of Rome, Italy
    New Microbiol 29:89-100. 2006
    ....
  8. doi request reprint Selected amino acid changes in HIV-1 subtype-C gp41 are associated with specific gp120(V3) signatures in the regulation of co-receptor usage
    Salvatore Dimonte
    University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Virus Res 168:73-83. 2012
    ..These findings strengthen previous observations that determinants of tropism may also reside in the gp41 protein...
  9. doi request reprint Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia
    Valentina Svicher
    University of Rome Tor Vergata, Italy
    Dig Liver Dis 42:902-7. 2010
    ..To investigate lamivudine (LAM)-resistance profiles of hepatitis B virus (HBV) at the early stages of virological breakthrough (serum HBV-DNA 12-345IU/ml) or when HBV-DNA is undetectable...
  10. pmc Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs
    Claudia Alteri
    Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata Rome, Italy
    BMC Infect Dis 9:111. 2009
    ..This study is aimed to assess the prevalence and the patterns of the mutations recently associated with transmitted drug resistance in the reverse transcriptase (RT) and in protease (PR) of HIV-1...
  11. ncbi request reprint Subtype analysis and mutations to antiviral drugs in HIV-1-infected patients from Mozambique before initiation of antiretroviral therapy: results from the DREAM programme
    Maria Concetta Bellocchi
    INMI L, Spallanzani, Rome, Italy
    J Med Virol 76:452-8. 2005
    ..The high frequency of secondary mutations/polymorphisms in HIV-PR deserves further studies to evaluate its relevance in clinical settings...
  12. pmc Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Virol 81:11507-19. 2007
    ..Mutations beyond those currently known to confer resistance should be considered for a better prediction of clinical response to reverse transcriptase inhibitors and for the development of more efficient new-generation NNRTIs...
  13. pmc HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors
    Valeria Cento
    Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata, Rome, Italy
    PLoS ONE 7:e39652. 2012
    ..Because of the extreme genetic variability of hepatitis C virus (HCV), we analyzed whether specific HCV-genotypes are differently prone to develop resistance to linear and macrocyclic protease-inhibitors (PIs)...
  14. pmc Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Virol 80:7186-98. 2006
    ....
  15. doi request reprint Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution
    Valeria Cento
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
    J Gen Virol 94:143-9. 2013
    ..Highly conserved regions in RT and HBsAg may deserve further attention as novel therapeutic targets...
  16. doi request reprint Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage
    Valentina Svicher
    Department of Experimental Medicine and Biochemical Sciences, University of Tor Vergata, Rome, Italy
    Antivir Ther 16:1035-45. 2011
    ..Knowledge of how different genetic signatures of gp120 V3 domain effect the strength of this interaction is limited...
  17. doi request reprint Late hepatitis B virus reactivation after lamivudine prophylaxis interruption in an anti-HBs-positive and anti-HBc-negative patient treated with rituximab-containing therapy
    Laura Ceccarelli
    Infectious Disease Unit, Tor Vergata University Hospital, Rome, Italy
    J Infect 65:180-3. 2012
    ..Furthermore, it is of outstanding importance to identify alternative markers (e.g. cccDNA, HBV core related antigen, etc.), that could be predictive of HBV reactivation...
  18. ncbi request reprint Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group
    Valentina Svicher
    Department of Experimental Medicine, University of Rome, Roma, Italy
    New Microbiol 35:17-25. 2012
    ..The DIVA study is aimed at setting up a standardized genotypic tropism-testing on proviral-DNA for the routine clinical diagnostic-laboratory...
  19. pmc The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing
    Valentina Svicher
    Department of Experimental Medicine and Surgery, University of Tor Vergata Rome, Italy
    PLoS ONE 8:e53603. 2013
    ..We evaluated the correlation between FPR obtained by V3 population-sequencing and the burden of CXCR4-using variants detected by V3 ultra-deep sequencing (UDPS) and Enhanced-Sensitivity Trofile assay (ESTA)...
  20. doi request reprint Genetic and structural analysis of HIV-1 Rev responsive element related to V38A and T18A enfuvirtide resistance mutations
    Salvatore Dimonte
    University of Rome Tor Vergata, Rome, Italy salvatore dimonte uniroma2 it
    Intervirology 55:385-90. 2012
    ..We previously found the co-presence of V38A+T18A resistance mutations in patients failing enfuvirtide...
  21. doi request reprint Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Antimicrob Chemother 65:2305-18. 2010
    ..To define whether the prevalence of mutations associated with integrase inhibitor (INI) resistance is different in untreated versus antiretroviral-treated HIV-1-infected individuals (all INI naive)...
  22. ncbi request reprint Mechanisms underlying activity of antiretroviral drugs in HIV-1-infected macrophages: new therapeutic strategies
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome, Rome, Italy
    J Leukoc Biol 80:1103-10. 2006
    ..A better understanding of the activity of the anti-HIV drugs in M/M may represent a key element for the design of effective anti-HIV chemotherapy...
  23. pmc High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations
    Francesca Ceccherini-Silberstein
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    J Virol 79:10718-29. 2005
    ..This new knowledge could be of help in the structure-based design of novel resistance-evading drugs...
  24. pmc Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v₃ signatures in the regulation of co-receptor usage
    Salvatore Dimonte
    University of Rome Tor Vergata, Via Montpellier 1, Rome, Italy
    Retrovirology 8:33. 2011
    ..The binomial correlation phi coefficient was used to assess covariation among gp120V3 and gp41 mutations; subsequently the average linkage hierarchical agglomerative clustering was performed...
  25. doi request reprint Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development
    Valentina Svicher
    Department of Experimental Medicine and Biochemical Science, University of Tor Vergata Rome, Italy
    Dig Liver Dis 43:975-83. 2011
    ..Impact of hepatitis B virus genetic barrier, defined as the number and type of nucleotide substitutions required to overcome drug/immune selective pressure, on drug-resistance/immune-escape development is unknown...
  26. ncbi request reprint Does residual virus replication during successful HAART lead to HIV-1 genetic evolution?
    Stefano Aquaro
    Department of Pharmaco Biology, University of Carabria, Reude, Rome, Italy
    J HIV Ther 11:84-8. 2006
  27. doi request reprint The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
    J Hepatol 50:461-70. 2009
    ..To investigate the different clusters of mutations associated with lamivudine resistance in HBV genotypes D and A...
  28. doi request reprint Structural modifications induced by specific HIV-1 protease-compensatory mutations have an impact on the virological response to a first-line lopinavir/ritonavir-containing regimen
    Claudia Alteri
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
    J Antimicrob Chemother 68:2205-9. 2013
    ....
  29. ncbi request reprint Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group
    Valentina Svicher
    University of Rome Tor Vergata, Department of Experimental Medicine, Roma, Italy
    New Microbiol 33:195-206. 2010
    ..The goal of the OSCAR programme is to evaluate the performances of genotypic HIV-1 tropism testing in clinical practice using the enhanced sensitivity version of Trofile (ESTA) as reference-assay...
  30. doi request reprint Impact of pre-therapy viral load on virological response to modern first-line HAART
    Maria Mercedes Santoro
    University of Rome Tor Vergata, Rome, Italy
    Antivir Ther 18:867-76. 2013
    ..We tested whether pre-HAART viraemia affects the achievement and maintenance of virological success in HIV-1-infected patients starting modern first-line therapies...
  31. doi request reprint Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen
    Valeria Cento
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, 00100 Rome, Italy
    J Infect 67:303-12. 2013
    ..Furthermore, due to HBV-RT/HBsAg gene-overlap, they can have an impact on HBsAg-detection and quantification...
  32. pmc Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages
    Matteo Surdo
    Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
    PLoS ONE 8:e68076. 2013
    ....
  33. doi request reprint HIV-2 A-subtype gp125c₂-v₃-c₃ mutations and their association with CCR5 and CXCR4 tropism
    Salvatore Dimonte
    Virology, Department of Experimental Medicine and Biochemistry, Tor Vergata University, Via Montpellier 1, 00133 Rome, Italy
    Arch Virol 156:1943-51. 2011
    ..Finally, R5 associations, two strong subclusters were observed, grouping several C2-V3-C3 mutated positions. These data indicate the possible contribution of C2-V3-C3 mutational patterns in regulating HIV-2 tropism...
  34. doi request reprint 'Sentinel' mutations in standard population sequencing can predict the presence of HIV-1 reverse transcriptase major mutations detectable only by ultra-deep pyrosequencing
    Claudia Alteri
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
    J Antimicrob Chemother 66:2615-23. 2011
    ....
  35. ncbi request reprint HIV-1-associated dementia during HAART therapy
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Rome, Italy
    Recent Pat CNS Drug Discov 3:23-33. 2008
    ..In this review, we outline the current state of knowledge regarding the pathophysiology of CNS injury in HIV-1 infection and will focus on the effects of HAART on CNS...
  36. doi request reprint HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Antiviral Res 90:42-53. 2011
    ....
  37. ncbi request reprint Novel drug resistance mutations in HIV: recognition and clinical relevance
    Carlo Federico Perno
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Italy
    AIDS Rev 8:179-90. 2006
    ..Such novel mutations should be considered for improved prediction of clinical response to antiretroviral drugs and for assessing the efficacy of next-generation drugs...
  38. ncbi request reprint Limited development and progression of resistance of HIV-1 to the nucleoside analogue reverse transcriptase inhibitor lamivudine in human primary macrophages
    Stefano Aquaro
    Department of Experimental Medicine and Biochemical Sciences, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome
    J Antimicrob Chemother 55:872-8. 2005
    ....
  39. pmc Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors
    Valentina Svicher
    Department of Experimental Medicine, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy
    Antimicrob Agents Chemother 49:2015-25. 2005
    ....
  40. ncbi request reprint Therapeutic strategies towards HIV-1 infection in macrophages
    Carlo Federico Perno
    National Institute for Infectious Diseases L Spallanzani, Via Portuense 292, 00149 Rome, Italy
    Antiviral Res 71:293-300. 2006
    ..Moreover, testing new and promising antiviral compounds in such cells may provide crucial hints about their efficacy in patients infected by HIV...
  41. doi request reprint Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence
    Ilaria Lenci
    Hepatology, Tor Vergata University, Rome, Italy
    J Hepatol 55:587-93. 2011
    ..HBV reactivation after liver transplantation may be related to persistence of covalently closed circular (ccc) DNA. We investigated the safety of HBV prophylaxis withdrawal in selected HBV transplanted patients...